The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a greater substantial loss in body weight and improve metabolic markers, parti